Online inquiry

IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2105MR)

This product GTTS-WQ2105MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IFNAR1&IFNAR2 gene. The antibody can be applied in Hepatitis C research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000629.3; NM_000874.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3454; 3455
UniProt ID P17181; P48551
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ2105MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ9630MR IVTScrip™ mRNA-Anti-PDCD1, JNJ-63723283(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA JNJ-63723283
GTTS-WQ10143MR IVTScrip™ mRNA-Anti-CGRP, LBR-101(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LBR-101
GTTS-WQ13576MR IVTScrip™ mRNA-Anti-IL13, QAX-576(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA QAX-576
GTTS-WQ3072MR IVTScrip™ mRNA-Anti-TFPI, Anti-TFPI(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA Anti-TFPI
GTTS-WQ8896MR IVTScrip™ mRNA-Anti-IGHE, IGE25(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IGE25
GTTS-WQ4269MR IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BIIB-033
GTTS-WQ12403MR IVTScrip™ mRNA-Anti-CD3E, NI-0401(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA NI-0401
GTTS-WQ9683MR IVTScrip™ mRNA-Anti-KLRK1, JNJ-64304500(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-64304500
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW